120 related articles for article (PubMed ID: 36976911)
1. The involvement of Aurora-A and p53 in oxaliplatin-resistant colon cancer cells.
Chen MC; Yang BZ; Kuo WW; Wu SH; Wang TF; Yeh YL; Chen MC; Huang CY
J Cell Biochem; 2023 Apr; 124(4):619-632. PubMed ID: 36976911
[TBL] [Abstract][Full Text] [Related]
2. Thermotherapy enhances oxaliplatin-induced cytotoxicity in human colon carcinoma cells.
Zhang XL; Hu AB; Cui SZ; Wei HB
World J Gastroenterol; 2012 Feb; 18(7):646-53. PubMed ID: 22363135
[TBL] [Abstract][Full Text] [Related]
3. Establishment and biological characteristics of oxaliplatin-resistant human colon cancer cell lines.
Liu Z; Qiu M; Tang QL; Liu M; Lang N; Bi F
Chin J Cancer; 2010 Jul; 29(7):661-7. PubMed ID: 20591218
[TBL] [Abstract][Full Text] [Related]
4. Oxaliplatin activity in selected and unselected human ovarian and colorectal cancer cell lines.
Noordhuis P; Laan AC; van de Born K; Losekoot N; Kathmann I; Peters GJ
Biochem Pharmacol; 2008 Jul; 76(1):53-61. PubMed ID: 18508032
[TBL] [Abstract][Full Text] [Related]
5. Metformin revert insulin-induced oxaliplatin resistance by activating mitochondrial apoptosis pathway in human colon cancer HCT116 cells.
Liu C; Liu Q; Yan A; Chang H; Ding Y; Tao J; Qiao C
Cancer Med; 2020 Jun; 9(11):3875-3884. PubMed ID: 32248666
[TBL] [Abstract][Full Text] [Related]
6. TRIM29 Reverses Oxaliplatin Resistance of P53 Mutant Colon Cancer Cell.
Lei G; Liu S; Yang X; He C
Can J Gastroenterol Hepatol; 2021; 2021():8870907. PubMed ID: 33824865
[TBL] [Abstract][Full Text] [Related]
7. Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels.
Giovannetti E; Backus HH; Wouters D; Ferreira CG; van Houten VM; Brakenhoff RH; Poupon MF; Azzarello A; Pinedo HM; Peters GJ
Br J Cancer; 2007 Mar; 96(5):769-75. PubMed ID: 17339891
[TBL] [Abstract][Full Text] [Related]
8. AURKA Increase the Chemosensitivity of Colon Cancer Cells to Oxaliplatin by Inhibiting the TP53-Mediated DNA Damage Response Genes.
Shan B; Zhao R; Zhou J; Zhang M; Qi X; Wang T; Gong J; Wu Y; Zhu Y; Yang W; Zhang Y; Wang G; Li X
Biomed Res Int; 2020; 2020():8916729. PubMed ID: 32851091
[TBL] [Abstract][Full Text] [Related]
9. Higher anti-tumour efficacy of platinum(IV) complex LA-12 is associated with its ability to bypass M-phase entry block induced in oxaliplatin-treated human colon cancer cells.
Vondálová Blanářová O; Jelínková I; Hyršlová Vaculová A; Sova P; Hofmanová J; Kozubík A
Cell Prolif; 2013 Dec; 46(6):665-76. PubMed ID: 24118195
[TBL] [Abstract][Full Text] [Related]
10. CIAPIN1 confers multidrug resistance through up-regulation of MDR-1 and Bcl-L in LoVo/Adr cells and is independent of p53.
Zhang YF; Li XH; Shi YQ; Wu YY; Li N; He Q; Ji Q; Wang RQ; Yang SM; Fang DC
Oncol Rep; 2011 Apr; 25(4):1091-8. PubMed ID: 21240465
[TBL] [Abstract][Full Text] [Related]
11. p53 dependent and independent sensitivity to oxaliplatin of colon cancer cells.
Toscano F; Parmentier B; Fajoui ZE; Estornes Y; Chayvialle JA; Saurin JC; Abello J
Biochem Pharmacol; 2007 Aug; 74(3):392-406. PubMed ID: 17559811
[TBL] [Abstract][Full Text] [Related]
12. P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells.
Toscano F; Fajoui ZE; Gay F; Lalaoui N; Parmentier B; Chayvialle JA; Scoazec JY; Micheau O; Abello J; Saurin JC
Oncogene; 2008 Jul; 27(30):4161-71. PubMed ID: 18345033
[TBL] [Abstract][Full Text] [Related]
13. Chemosensitivity of human colon cancer cells is influenced by a p53-dependent enhancement of ceramide synthase 5 and induction of autophagy.
Brachtendorf S; Wanger RA; Birod K; Thomas D; Trautmann S; Wegner MS; Fuhrmann DC; Brüne B; Geisslinger G; Grösch S
Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Oct; 1863(10):1214-1227. PubMed ID: 30059758
[TBL] [Abstract][Full Text] [Related]
14. Regulation of tNOX expression through the ROS-p53-POU3F2 axis contributes to cellular responses against oxaliplatin in human colon cancer cells.
Chen HY; Islam A; Yuan TM; Chen SW; Liu PF; Chueh PJ
J Exp Clin Cancer Res; 2018 Jul; 37(1):161. PubMed ID: 30029680
[TBL] [Abstract][Full Text] [Related]
15. Curcumin β-D-glucuronide exhibits anti-tumor effects on oxaliplatin-resistant colon cancer with less toxicity in vivo.
Ozawa-Umeta H; Kishimoto A; Imaizumi A; Hashimoto T; Asakura T; Kakeya H; Kanai M
Cancer Sci; 2020 May; 111(5):1785-1793. PubMed ID: 32163218
[TBL] [Abstract][Full Text] [Related]
16. The effect and mechanism of erianin on the reversal of oxaliplatin resistance in human colon cancer cells.
Su C; Liu S; Ma X; Liu J; Liu J; Lei M; Cao Y
Cell Biol Int; 2021 Dec; 45(12):2420-2428. PubMed ID: 34351659
[TBL] [Abstract][Full Text] [Related]
17. The glutamate transport inhibitor DL-Threo-β-Benzyloxyaspartic acid (DL-TBOA) differentially affects SN38- and oxaliplatin-induced death of drug-resistant colorectal cancer cells.
Pedraz-Cuesta E; Christensen S; Jensen AA; Jensen NF; Bunch L; Romer MU; Brünner N; Stenvang J; Pedersen SF
BMC Cancer; 2015 May; 15():411. PubMed ID: 25981639
[TBL] [Abstract][Full Text] [Related]
18. β-Cryptoxanthin Synergistically Enhances the Antitumoral Activity of Oxaliplatin through ΔNP73 Negative Regulation in Colon Cancer.
San Millán C; Soldevilla B; Martín P; Gil-Calderón B; Compte M; Pérez-Sacristán B; Donoso E; Peña C; Romero J; Granado-Lorencio F; Bonilla F; Domínguez G
Clin Cancer Res; 2015 Oct; 21(19):4398-409. PubMed ID: 26023082
[TBL] [Abstract][Full Text] [Related]
19. The tyrosine phosphatase SHP2 promotes proliferation and oxaliplatin resistance of colon cancer cells through AKT and ERK.
Yu M; Xu C; Zhang H; Lun J; Wang L; Zhang G; Fang J
Biochem Biophys Res Commun; 2021 Jul; 563():1-7. PubMed ID: 34052504
[TBL] [Abstract][Full Text] [Related]
20. Methyl Sartortuoate Inhibits Colon Cancer Cell Growth by Inducing Apoptosis and G2/M-Phase Arrest.
Lan Q; Li S; Lai W; Xu H; Zhang Y; Zeng Y; Lan W; Chu Z
Int J Mol Sci; 2015 Aug; 16(8):19401-18. PubMed ID: 26287184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
